Minnesota

Minnesota’s policy pipeline is unusually legible because the task force process was public and methodical. MDH’s public page documents monthly meetings from Nov 2023 through Dec 2024, with agendas, slides, summaries and formal reports. For researchers, that archive matters because it shows a state building an evidentiary and administrative scaffold before enacting access law.###

Several major bills followed. HF 2699 in 2025 proposed adult-use authorisation, protections, harm-reduction programming and a Psychedelic Medicine Board, but the reviewed record shows only introduction and referral to House Health Finance and Policy. HF 2906, a therapeutic-use bill, had a committee report on 16 Mar 2026 to adopt as amended and re-refer it to Commerce Finance and Policy. Senate companion activity also continued, including SF 4485’s introduction and referral to Health and Human Services in Mar 2026.###

In practical access terms, that means Minnesota is closer to a serious regulatory conversation than most of the states in this batch, but it is still not a live programme. The distance between a task-force recommendation and patient access remains substantial because rulemaking, interagency agreements, registries, treatment-facility licensing and contraindication screening have not yet been activated in law.###

University of Minnesota is a credible psychedelics research node. In Dec 2021, the medical school announced a mechanistic clinical psilocybin study led by Jessica Nielson to examine how psilocybin alters brain function; the university said it was enrolling up to 46 carefully vetted participants and that dosing would occur under clinician supervision within the M Health Fairview Clinical Research Unit.###

Minnesota is also strong on ketamine research and service infrastructure. Mayo Clinic’s Rochester pages list multiple ketamine studies, including long-term outcomes of a clinical ketamine service for treatment-resistant depression, a feasibility study on anterior cingulate GABA/glutamate change and remission, and additional infusion-related mechanistic work.###

The Minneapolis VA and University of Minnesota interface is also notable. The RISE Lab lists a current study on ketamine for major depressive disorder and post-traumatic stress disorder, with study visits at the Minneapolis VA and MRI at the University of Minnesota’s Center for Magnetic Resonance Research. That makes Minnesota one of the clearer VA-linked ketamine research states in this group.###

Minnesota’s main implementation story is still prospective. House Research’s summary of HF 2906 says the proposed psilocybin therapeutic use programme would be administered by the commissioner of health and the Office of Cannabis Management, with rulemaking, programme evaluation, data collection, research support, patient registration, facilitator licensing, cultivation oversight and testing built into the scheme. It would also cap programme scale during its first three years.###

The bill text itself places the commissioner of health at the centre of administration and rulemaking, requires a secure registration system, and defines treatment facilities, facilitators and qualifying medical conditions. In other words, Minnesota already has a reasonably detailed implementation blueprint on paper even though it has not yet crossed into enacted programme status.###

For access analysts, the punchline is straightforward: Minnesota has one of the clearest “if enacted, here is how it would run” pictures in the country, but there is still a hard line between blueprint and live access.###

The verified ecosystem is institutionally dense. University of Minnesota contributes psychedelic and ketamine research capacity through the Medical School, Jessica Nielson’s lab environment and the RISE Lab/Minneapolis VA interface. M Health Fairview provides the clearest verified clinical bridge into ordinary treatment-resistant-depression care.###

Mayo Clinic Rochester is the other major anchor, with both ongoing ketamine/esketamine-related study activity and a clinical-service dataset large enough to support observational follow-up. That combination of academic neuroscience, health-system delivery and visible bill architecture gives Minnesota broad ecosystem depth even before any psilocybin bill is enacted.###

Minnesota looks like a state where legislative refinement, rather than first-principles debate, will dominate the next 12–24 months. The task-force phase is finished; the questions now are whether therapeutic-use language can pass, how narrow the qualifying-condition list would be, and whether lawmakers are comfortable assigning large operational roles to both MDH and the Office of Cannabis Management.###

Even if a therapeutic-use bill passes, access would still lag. The proposed framework depends on rulemaking, data systems, testing standards, treatment-facility licensing, facilitator regulation and contraindication screening. That means Minnesota is closer to possible implementation than most peers here, but not close to immediate post-enactment patient access.###